168 related articles for article (PubMed ID: 27517676)
1. Pharmacokinetics, Biotransformation, and Excretion of [
Subramanian R; Zhu X; Hock MB; Sloey BJ; Wu B; Wilson SF; Egbuna O; Slatter JG; Xiao J; Skiles GL
Clin Pharmacokinet; 2017 Feb; 56(2):179-192. PubMed ID: 27517676
[TBL] [Abstract][Full Text] [Related]
2. Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis.
Wu L; Melhem M; Subramanian R; Wu B
J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):43-53. PubMed ID: 28063122
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis.
Wu B; Melhem M; Subramanian R; Chen P; Jaramilla Sloey B; Fouqueray B; Hock MB; Skiles GL; Chow AT; Lee E
J Clin Pharmacol; 2018 Jun; 58(6):717-726. PubMed ID: 29534286
[TBL] [Abstract][Full Text] [Related]
4. Nonclinical Pharmacokinetics, Disposition, and Drug-Drug Interaction Potential of a Novel d-Amino Acid Peptide Agonist of the Calcium-Sensing Receptor AMG 416 (Etelcalcetide).
Subramanian R; Zhu X; Kerr SJ; Esmay JD; Louie SW; Edson KZ; Walter S; Fitzsimmons M; Wagner M; Soto M; Pham R; Wilson SF; Skiles GL
Drug Metab Dispos; 2016 Aug; 44(8):1319-31. PubMed ID: 26895981
[TBL] [Abstract][Full Text] [Related]
5. Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing.
Edson KZ; Wu BM; Iyer A; Goodman W; Skiles GL; Subramanian R
Kidney Int Rep; 2016 May; 1(1):24-33. PubMed ID: 29318205
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of Parsabiv
Harada K; Fujioka A; Konno M; Inoue A; Yamada H; Hirota Y
Eur J Pharmacol; 2019 Jan; 842():139-145. PubMed ID: 30342948
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.
Chen P; Narayanan A; Wu B; Gisleskog PO; Gibbs JP; Chow AT; Melhem M
Clin Pharmacokinet; 2018 Jan; 57(1):71-85. PubMed ID: 28508378
[TBL] [Abstract][Full Text] [Related]
8. Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study.
Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Odani M; Akizawa T
Clin Ther; 2018 Dec; 40(12):2099-2111. PubMed ID: 30473399
[TBL] [Abstract][Full Text] [Related]
9. A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing Hemodialysis.
Xing C; Chen J; Zuo L; Fang Y; Ding X; Ni Z; Kong C; Shi G; Lu H; Hellawell J; Cheng S; Sohn W
Clin Ther; 2021 Nov; 43(11):2013-2023. PubMed ID: 34774334
[TBL] [Abstract][Full Text] [Related]
10. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
Block GA; Bushinsky DA; Cunningham J; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Mix TC; Moe SM; Patel UD; Silver J; Spiegel DM; Sterling L; Walsh L; Chertow GM
JAMA; 2017 Jan; 317(2):146-155. PubMed ID: 28097355
[TBL] [Abstract][Full Text] [Related]
11. Proof of Concept: First Pediatric [
van Groen BD; van Duijn E; de Vries A; Mooij MG; Tibboel D; Vaes WHJ; de Wildt SN
Clin Pharmacol Ther; 2020 Nov; 108(5):1003-1009. PubMed ID: 32386327
[TBL] [Abstract][Full Text] [Related]
12. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
13. Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore.
Khan BA; Qu X; Hua Y; Javaid MM
Cureus; 2023 Nov; 15(11):e48186. PubMed ID: 38050530
[TBL] [Abstract][Full Text] [Related]
14. Nonclinical Safety Profile of Etelcalcetide, a Novel Peptide Calcimimetic for the Treatment of Secondary Hyperparathyroidism.
Fielden MR; Dean C; Black K; Sawant SG; Subramanian R; Tomlinson JE; Walter S; Zimmermann C; Griggs MW; McKeon ME; Lewis EM; Beevers C; Pyrah I
Int J Toxicol; 2016 May; 35(3):294-308. PubMed ID: 26941242
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, Excretion, and Mass Balance of [
Ambery C; Young G; Fuller T; Lazaar AL; Pereira A; Hughes A; Ramsay D; van den Berg F; Daley-Yates P
Clin Pharmacol Drug Dev; 2018 Nov; 7(8):901-910. PubMed ID: 30230263
[TBL] [Abstract][Full Text] [Related]
16. Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis.
Sohn W; Salusky IB; Schmitt CP; Taylan C; Walle JV; Ngang J; Yan L; Kroenke M; Warady BA
Pediatr Nephrol; 2021 Jan; 36(1):133-142. PubMed ID: 32647975
[TBL] [Abstract][Full Text] [Related]
17. A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients
.
Yokoyama K; Fukagawa M; Shigematsu T; Akiba T; Fujii A; Odani M; Akizawa T
Clin Nephrol; 2017 Aug; 88(2):68-78. PubMed ID: 28671062
[TBL] [Abstract][Full Text] [Related]
18. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
[TBL] [Abstract][Full Text] [Related]
19. Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
Friedl C; Zitt E
Drug Des Devel Ther; 2018; 12():1589-1598. PubMed ID: 29910605
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Shoji T; Nakatani S; Kabata D; Mori K; Shintani A; Yoshida H; Takahashi K; Ota K; Fujii H; Ueda S; Nishi S; Nakatani T; Yoshiyama M; Goto K; Hamada T; Imanishi M; Ishimura E; Kagitani S; Kato Y; Kumeda Y; Maekawa K; Matsumura T; Nagayama H; Obi Y; Ohno Y; Sai Y; Sakurai M; Sasaki S; Shidara K; Shoji S; Tsujimoto Y; Yamakawa K; Yasuda H; Yodoi S; Inaba M; Emoto M
Clin J Am Soc Nephrol; 2021 Apr; 16(4):599-612. PubMed ID: 33685864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]